title: Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF-β-dependent G1 cell cycle arrest.
abstract: The mammalian target of rapamycin complex 1 (mTORC1) is a critical regulator of cap-dependent translation through its direct activation of ribosomal protein p70 S6 kinase (S6 kinase) and indirect activation of eukaryotic initiation factor 4E (eIF4E). We recently reported that inhibition of eIF4E expression caused apoptosis in cancer cells in the absence of serum. This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E. We report here that knockdown of eIF4E also causes apoptosis in the presence of serum. This was unexpected because rapamycin induces G1 cell cycle arrest in the presence of serum. Upon investigation, we have found that inactivated S6 kinase prevents the apoptotic effect observed by singular knockdown of eIF4E and results in G1 cell cycle arrest. This effect is dependent on TGF-β (transforming growth factor-β) signaling which contributes to G1 cell cycle arrest. Suppression of S6 kinase phosphorylation alone is insufficient to mediate cell cycle arrest, indicating that complete G1 cell cycle arrest is due to suppression of both S6 kinase and eIF4E. These data indicate that the cytostatic effect of rapamycin is suppression of both S6 kinase and eIF4E, while the cytotoxic effects are due suppression of eIF4E in the absence of S6 kinase-dependent activation of TGF-β signals. Our findings place an importance on the evaluating the activity/expression level of S6 kinase and eIF4E as readouts for rapamycin/rapalog efficacy.
authors: Department of Biological Sciences, Hunter College of The City University of New York, 695 Park Avenue, New York, NY 10065, USA.
authors: Paige
authors: P
authors: Yellen
authors: Amrita
authors: A
authors: Chatterjee
authors: Angela
authors: A
authors: Preda
authors: David A
authors: DA
authors: Foster
mesh_terms: D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D045744:Cell Line, Tumor; D039561:Eukaryotic Initiation Factor-4E / Q000235:genetics* / Q000378:metabolism; D059585:G1 Phase Cell Cycle Checkpoints / Q000187:drug effects / Q000502:physiology*; D055785:Gene Knockdown Techniques; D006801:Humans; D010766:Phosphorylation / Q000187:drug effects; D019893:Ribosomal Protein S6 Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D044967:Serum; D020123:Sirolimus / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000378:metabolism*
chemical_list: D039561:Eukaryotic Initiation Factor-4E; D016212:Transforming Growth Factor beta; D019893:Ribosomal Protein S6 Kinases; D020123:Sirolimus
references: Mol Cell Biol. 2004 Jan;24(1):200-16
references: 14673156
references: PLoS Med. 2008 Jan 22;5(1):e8
references: 18215105
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Cancer Cell. 2002 Jul;2(1):25-8
references: 12150822
references: Nature. 1983 Aug 18-24;304(5927):596-602
references: 6308472
references: Cell Cycle. 2007 Nov 15;6(22):2840-5
references: 18032924
references: Am J Physiol Renal Physiol. 2003 Sep;285(3):F413-22
references: 12759229
references: Oncogene. 2005 Apr 21;24(18):3067-72
references: 15735725
references: Cancer Res. 2006 Feb 1;66(3):1500-8
references: 16452206
references: Mol Cell. 2006 Apr 21;22(2):159-68
references: 16603397
references: Cancer Cell. 2004 Jun;5(6):519-23
references: 15193254
references: Cancer Cell. 2010 Mar 16;17(3):249-61
references: 20227039
references: Mol Cell Biol. 2009 Mar;29(6):1411-20
references: 19114562
references: Hepatology. 2009 Jul;50(1):216-29
references: 19437488
references: Oncogene. 2003 Jun 19;22(25):3937-42
references: 12813467
references: Oncogene. 2008 Feb 14;27(8):1055-62
references: 17700525
references: Cell Cycle. 2009 Feb 15;8(4):567-72
references: 19197153
references: Oncogene. 2005 Jan 20;24(4):672-9
references: 15580312
references: Genes Dev. 2001 Nov 1;15(21):2852-64
references: 11691836
references: Expert Opin Ther Targets. 2004 Dec;8(6):551-64
references: 15584862
references: Eur J Cancer. 2005 Sep;41(14):2060-70
references: 16125380
references: Cancer Res. 2005 Aug 15;65(16):7052-8
references: 16103051
references: Mol Cell. 2007 Oct 12;28(1):28-40
references: 17936702
references: J Biol Chem. 2002 Jan 18;277(3):1974-80
references: 11713246
references: Nature. 2005 Feb 3;433(7025):477-80
references: 15690031
references: J Clin Oncol. 2008 Apr 1;26(10):1603-10
references: 18332469
references: EMBO J. 2006 Jan 11;25(1):58-69
references: 16362038
references: Cell Cycle. 2011 Nov 15;10(22):3948-56
references: 22071574
references: Cell. 2008 Jul 25;134(2):215-30
references: 18662538
references: Drug Discov Today. 2011 Apr;16(7-8):325-31
references: 21333749
references: Science. 2010 May 28;328(5982):1172-6
references: 20508131
references: Mol Cancer. 2011 Jul 26;10:90
references: 21791089
references: Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9666-70
references: 11493700